Case number 1:17-cv-01073
AstraZeneca LP et al v. InvaGen Pharmaceuticals Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Jun 20, 2020 | 1 | Complaint (10) |
| Mar 15, 2018 | 13 | Patent/Trademark Report to Commissioner (1) |
| Mar 15, 2018 | 13 | Consent Judgment (3) |
| Mar 15, 2018 | 13 | Main Document (1) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) RE 46,276; 7,250,419; 7,265,124. (Attachments: # (1) Consent Judgment)(nms) |
| Mar 9, 2018 | N/A | Terminated Case (0) Docket Text: CASE CLOSED per D.I. 446 in Lead Civil Action 15-1000-RGA. (nms) |
| Oct 16, 2017 | 12 | SO ORDERED (3) Docket Text: SO ORDERED, Granting (11 in 17-cv-1073-RGA, 362 in 15-cv-1000-RGA) Joint Stipulation and Order to Consolidate. Signed by Judge Richard G. Andrews on 10/16/2017. Associated Cases: 1:15-cv-01000-RGA, 1:17-cv-01073-RGA(nms) |
| Oct 13, 2017 | 11 | Stipulation (3) Docket Text: Joint STIPULATION and [Proposed] Order to Consolidate by AstraZeneca AB, AstraZeneca LP, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited. (Silver, Daniel) |
| Oct 3, 2017 | 9 | Answer to Complaint (20) Docket Text: ANSWER to [1] Complaint, and COUNTERCLAIMS against AstraZeneca AB, AstraZeneca LP, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited, by InvaGen Pharmaceuticals Inc..(Myer, R.) Modified on 10/4/2017 (nms). |
| Oct 3, 2017 | 10 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Cipla (EU) Limited,, Corporate Parent Cipla Limited. for InvaGen Pharmaceuticals Inc., InvaGen Pharmaceuticals Inc. filed by InvaGen Pharmaceuticals Inc.. (Myer, R.) |
| Aug 9, 2017 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. (rjb) |
| Aug 2, 2017 | N/A | No Summons Issued (0) Docket Text: No Summons Issued. (crb) |
| Aug 2, 2017 | 1 | Exhibit A (20) |
| Aug 2, 2017 | 1 | Exhibit B (16) |
| Aug 2, 2017 | 1 | Exhibit C (17) |
| Aug 2, 2017 | 1 | Civil Cover Sheet (2) |
| Aug 2, 2017 | 2 | Magistrate Consent Forms (3) Docket Text: Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (crb) |
| Aug 2, 2017 | 3 | ANDA Form (2) Docket Text: Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 6/30/2017. Date of Expiration of Patent: See Attachment.Thirty Month Stay Deadline: 12/30/2019. (crb) |
| Aug 2, 2017 | 4 | Patent/Trademark Report to Commissioner (1) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) RE46,276; 7,250,419; 7,265,124. (crb) |
| Aug 2, 2017 | 5 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent AstraZeneca PLC for AstraZeneca AB filed by AstraZeneca AB. (crb) |
| Aug 2, 2017 | 6 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent AstraZeneca PLC for AstraZeneca LP filed by AstraZeneca LP. (crb) |
| Aug 2, 2017 | 7 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent AstraZeneca PLC for AstraZeneca Pharmaceuticals LP filed by AstraZeneca Pharmaceuticals LP. (crb) |
| Aug 2, 2017 | 8 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent AstraZeneca PLC for AstraZeneca UK Limited filed by AstraZeneca UK Limited. (crb) |
| Aug 2, 2017 | 1 | Main Document (10) Docket Text: COMPLAINT FOR PATENT INFRINGEMENT filed against InvaGen Pharmaceuticals Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-2195330.) - filed by AstraZeneca LP, AstraZeneca UK Limited, AstraZeneca Pharmaceuticals LP, AstraZeneca AB. (Attachments: # (1) Exhibit A, # (2) Exhibit B, # (3) Exhibit C, # (4) Civil Cover Sheet)(crb) |
| Aug 2, 2017 | 1 | Complaint* (1) |
